Possible new principle for cancer therapy

February 14, 2018, Karolinska Institutet
Credit: CC0 Public Domain

A study published in Science Translational Medicine shows that small molecules that specifically inhibit an important selenium-containing enzyme may be useful in combating cancer. When researchers at Karolinska Institutet in Sweden treated cancer in mice using these molecules, they observed rapid tumoricidal effects. Researchers now hope that this new principle for cancer treatment will eventually be developed for use in humans.

Humans need the chemical element selenium for good health. The selenium-containing enzyme thioredoxin reductase 1 (TrxR1) can be used to support the growth of cells and to protect them from harmful forms of oxygen radicals that cause oxidative stress. Selenium intake has long been connected with , although the correlation between selenium and cancer growth is extremely complex and not fully understood.

Raised levels of TrxR1 can be seen in several forms of cancer and are linked to worse prognoses in head and neck, lung and breast cancers. Researchers therefore analysed almost 400,000 in the search for new and more specific TrxR1 inhibitors than those previously available. They discovered three molecules that met their search criteria. Sure enough, when tested, these same molecules also proved to be active as cancer medicines. The researchers were able to treat over 60 types of cancer cells under laboratory conditions. Normal cells were, however, much less sensitive to these molecules.

"This effectiveness against cancer may be a result of cancer cells' seemingly greater sensitivity to when compared to , which in turn can be utilised in cancer therapy," says Professor Elias Arnér, Department of Medical Biochemistry and Biophysics at Karolinska Institutet, who led the study.

Researchers also found rapid tumoricidal effects when treating head and neck or breast cancers in mice, without obvious side-effects. The new molecules have yet to be tested on humans, but it is already known that several different cancer medicines currently in use, including cisplatin and melfalan, inhibit TrxR1. Thus far, whether or not this inhibition of the enzyme is important to the effectiveness of these medicines has remained unknown, but this study suggests that this might well be the case. Researchers now intend to further develop the new TrxR1 inhibitors to offer a new form of cancer therapy.

"My hope is that we will be able to develop new treatments, effective against multiple forms of cancer but with few side-effects. This seems to work in mouse models and we are therefore hopeful that this principle for treatment can be developed for humans, even if this will require many years of further research," says Elias Arnér.

Explore further: New way to target the growth of breast cancer cells

More information: "Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy". William C Stafford, Xiaoxiao Peng, Maria Hägg Olofsson, Xiaonan Zhang, Diane K Luci, Li Lu, Qing Cheng, Lionel Trésaugues, Thomas S Dexheimer, Nathan P Coussens, Martin Augsten, Hanna-Stina Martinsson Ahlzén, Owe Orwar, Arne Östman, Sharon Stone-Elander, David J Maloney, Ajit Jadhav, Anton Simeonov, Stig Linder och Elias S.J. Arnér. Science Translational Medicine, online 14 February 2018. stm.sciencemag.org/lookup/doi/ … scitranslmed.aaf7444

Related Stories

New way to target the growth of breast cancer cells

January 18, 2018
An international team of researchers led from Karolinska Institutet and Science for Life Laboratory in Sweden have found a new way of halting the growth of breast cancer cells. In their study, which is published in Nature ...

Oestrogen causes neuroblastoma cells to mature into neurons

January 29, 2018
The female sex hormone oestrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers at Karolinska Institutet in Sweden demonstrate that ...

Potential therapy identified for aggressive breast cancer

January 25, 2018
The European Cancer Stem Cell Research Institute, based with Cardiff University, has repurposed a current cancer therapy, TRAIL, to find a new treatment for advanced cancers that are resistant to anti-hormone therapy.

New possible target for cancer treatment

June 6, 2017
Scientists at Karolinska Institutet in Sweden report that cancer cells and normal cells use different 'gene switches' in order to regulate the expression of genes that control growth. In mice, the removal of a large regulatory ...

Targeting breast cancer through precision medicine

January 9, 2018
University of Alberta researchers have discovered a mechanism that may make cancer cells more susceptible to treatment. The research team found that the protein RYBP prevents DNA repair in cancer cells, including breast cancer.

Recommended for you

Fully reprogrammed virus offers new hope as cancer treatment

May 25, 2018
A cancer treatment that can completely destroy cancer cells without affecting healthy cells could soon be a possibility, thanks to research led by Cardiff University.

Study finds gut microbiome can control antitumor immune function in liver

May 24, 2018
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. Their study, published May 25 in Science, was led by researchers in the Center for Cancer Research (CCR) at the National ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation ...

Cancer cells co-opt pain-sensing 'wasabi receptor' to survive oxidative stress

May 24, 2018
Anyone who's taken a bite of a sandwich with too much spicy mustard or a piece of sushi with too much wasabi can attest to the tear-inducing sensation these condiments can cause. These loud warnings to the nervous system ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.